An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
- Conditions
- Unresectable Hepatocellular Carcinoma
- Registration Number
- NCT06117891
- Lead Sponsor
- Bayer
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria:<br><br> - Adult patients, = 18 years of age on the day of signing informed consent.<br><br> - Confirmed diagnosis of uHCC, treated in a first-line setting with AB or another<br> approved 1L-IO combo therapy.<br><br> - Decision to initiate treatment with a second-line systemic treatment was made as per<br> investigator's routine treatment practice prior to study enrollment.<br><br> - Signed informed consent or (for patients under legal age) signed informed assent by<br> the patient (where applicable) and signed informed consent by parents / legal<br> guardian.<br><br> - No participation in an investigational program with interventions outside of routine<br> clinical practice.<br><br>Exclusion Criteria:<br><br> - Not applicable
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival (OS)
- Secondary Outcome Measures
Name Time Method Discriptive analysis of demographic characteristics;Discriptive analysis of clinical characteristics;Duration of therapy (DoT);Progression-free survival (PFS);Best overall response rate (ORR);Treatment sequences post first-line AB or other IO combinations